Life Sciences

July 16 open house highlights expanded sterile filling contract manufacturing capabilities for small and large molecules Minneapolis, MN – July 2, 2025 – Pace® Life Sciences, LLC, a U.S.-based contract research, development, and manufacturing organization (CRDMO) and a Division of Pace®, a Science and Technology Company, builds upon its growth in the pharma and biotech […]

Company confirms high standards for data integrity and quality systems  MINNEAPOLIS, MN, May 20, 2025 Pace® Life Sciences, a U.S.-based full-service FDA-registered GMP Analytical Testing laboratory and contract, research, development and manufacturing organization (CRDMO) and a Division of Pace®, a Science and Technology Company, announced today a successful Pre-Approval Inspection (PAI) from The Food & Drug

With a growing network of locations across major US pharmaceutical hubs, Pace® aims to enhance customer experience through consistent quality and timely delivery.  Pace® Life Sciences, a biopharmaceutical services provider, has experienced significant growth through recent acquisitions of analytical labs, substantially increasing their testing capacity and scientific expertise. Looking ahead to 2025, Pace® is undertaking

Company stands out in Ethics, Environment, and Labor and Human Rights focus areas for 2024  Minneapolis, MN – April 1, 2025 –Pace® Life Sciences, LLC, a U.S.-based contract research, development, and manufacturing organization (CRDMO) and a Division of Pace®, a Science and Technology Company, is pleased to announce that it has received a Bronze Medal award

The modern therapeutic landscape is defined by an ever-growing portfolio of complex drug products – from biologics and gene therapies to mRNA-based vaccines and monoclonal antibodies. These therapies, which often involve intricate fomulations and require advanced sterile processing, have fundamentally altered the demands placed on fill-finish operations. Frank Tagliaferri, chief scientific officer at Pace® Life

Company expands sterile fill-finish services, capacity for biologics development and manufacturing, and more. Minneapolis, MN – January 10, 2025 – Pace® Life Sciences, LLC, a U.S.-based contract research, development, and manufacturing organization (CRDMO) and a Division of Pace®, a Science and Technology Company, today announced significant growth plans for two of the company’s locations. Pace® Life

Alternative delivery methods for biologics continues to be explored that offer less invasive, less painful administration. Despite their track record of demonstrating significant therapeutic efficacy, biologics still face daunting challenges in their drug delivery. Biologics such as monoclonal antibodies (mAbs) and some vaccines are largely administered via injection or by infusion. These methods can often